Hualei Bu

The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients

Xiaohua Wu, Lingying Wu, Beihua Kong et al. · International Journal of Gynecological Cancer · 2017 · 119 citations

Medicine, Gynecology, Oncology +17

Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer

Jinyu Meng, Jin Peng, Jie Feng et al. · Journal of Translational Medicine · 2021 · 60 citations · Full text

Life Sciences, Immunology, Oncology +17

An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian Cancer

Ning Li, Hualei Bu, Jihong Liu et al. · Clinical Cancer Research · 2021 · 55 citations · Full text

Medicine, Oncology, Pharmacology +13

FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner

Yu Wang, Chunping Qiu, Nan Lü et al. · International Journal of Oncology · 2018 · 50 citations · Full text

Medicine, Cell Biology, Oncology +17

Cyclin F and KIF20A, FOXM1 target genes, increase proliferation and invasion of ovarian cancer cells

Yingwei Li, Haiyang Guo, Zixiang Wang et al. · Experimental Cell Research · 2020 · 43 citations

Medicine, Cell Biology, Oncology +15